Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
132
resultados
Última actualización
30/04/2025 [06:58:00]
Resumen de: US2025127433A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; and a storage unit that stores the blood glucose measurement data, wherein the control unit stores the preset first verification data in the storage unit, and stores the blood glucose measurement data in the storage unit continuously to the first verification data.
Resumen de: US2025127439A1
A biometric wearable device (e.g. finger ring or smart watch) has optical sensors to measure body oxygenation level, hydration level, glucose level, heart rate, heart rate variability, and/or blood pressure. Light from light emitters is transmitted through body tissue and changes in the light are analyzed. The angles and/or vectors along which the light is transmitted through body tissue can be automatically changed by the device in order to scan different tissue regions and/or different tissue depths.
Resumen de: US2025132007A1
A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.
Resumen de: US2025127861A1
Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic/pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.
Resumen de: US2025127993A1
Disclosed are methods, techniques, systems, and devices that are operable to compensate for the effects of pharmaceuticals on a user's analyte measurement values, such as glucose levels and/or ketone levels. The disclosed system is configured to enable medicament delivery application to enter a pharmaceutical mode. While in pharmaceutical mode, the medicament delivery application is operable to adjust medicament delivery constraints and other settings used by the medicament delivery application to respond to the effects of the pharmaceutical on the user's analyte measurement values.
Resumen de: US2025127434A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; a storage unit that includes a plurality of storage areas and stores the blood glucose measurement data in the plurality of storage areas; and a communication unit that transmits the blood glucose measurement data stored in at least one of the plurality of storage areas to an external device.
Resumen de: US2025127429A1
A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a wearable device interior houses the VCSEL laser.
Resumen de: AU2023377269A1
A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.
Resumen de: US2023011856A1
An arrangement for operating a biosensor emitting radiation includes an excitation light source, which generates at least one excitation radiation for the biosensor; a coupling fiber, at the entry surface of which the excitation radiation is coupled in; an optical Y-coupler, including an excitation arm, which is connected to the exit surface of the coupling fiber, a detector arm, which is connected to an optical detector, and a sensor foot, which can be connected to the biosensor. The excitation arm has a conical shape. The radiation axis of the excitation arm includes an angle in the range of 5° to 70° with the main radiation axis of the detector arm. The diameter of the excitation arm at the connecting point to the detector arm is less than two thirds the diameter of the detector arm. An arrangement for determining the glucose content blood is also provided.
Resumen de: WO2025085172A1
A dialysis-ultrasound system is described that includes an ultrasound therapy device integrated with a catheter to incorporate ultrasound therapy into a dialysis system. The ultrasound device may be or may include a high-intensity focused ultrasound (HIFU) device or peripheral focused ultrasound stimulation (pFUS) device. The ultrasound therapy may target the liver, for example, to treat diabetes. In one example, a system includes a catheter configured to be arranged within the peritoneal cavity of a patient for peritoneal dialysis (PD), and an ultrasound device configured to emit ultrasound waves. The ultrasound device is integrated with the catheter and is arranged on the catheter to be implanted within the peritoneal cavity of the patient to provide ultrasound therapy to a target region of the patient. Other embodiments are described.
Resumen de: US2025132008A1
Systems and methods for processing sensor data are provided. In some embodiments, systems and methods are provided for calibration of a continuous analyte sensor. In some embodiments, systems and methods are provided for classification of a level of noise on a sensor signal. In some embodiments, systems and methods are provided for determining a rate of change for analyte concentration based on a continuous sensor signal. In some embodiments, systems and methods for alerting or alarming a patient based on prediction of glucose concentration are provided.
Resumen de: US2025127431A1
The invention provides a non-invasive blood glucose monitoring device with a wearing fit detection function, comprising a substrate, a blood glucose monitoring module, an optical feedback sensing module and at least one light-blocking wall. The substrate defines a first setting area for disposing the blood glucose monitoring module and a second setting area for disposing the optical feedback sensing module. The second setting area is between an edge of the substrate and the first setting area. The optical feedback sensing module includes at least one light-emitting element and at least one light-receiving element. Each light-emitting element emits a light signal corresponding to at least one specific wavelength, and each light-receiving element receives the light signal corresponding to the at least one specific wavelength, after being reflected, as a basis for determining the wearing fit. The at least one light-blocking wall is located between the first setting area and the second setting area.
Resumen de: US2025127436A1
The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.
Resumen de: US2025127432A1
A glucose monitoring system comprising: a glucose sensor configured to output a glucose sensor output signal indicative of an estimate of a glucose level of a user of the glucose monitoring system; a movement sensor configured to output a movement sensor output signal indicative of detected movement of the user; and a controller configured to generate an estimate of a current glucose level of the user based on the glucose sensor output signal and the movement sensor output signal.
Resumen de: US2025127435A1
A blood glucose sensing system includes a plurality of physiological sensors. The system can estimate blood glucose based on discrete invasive blood glucose estimates from a blood sample, discrete noninvasive blood glucose estimates derived from optical sensors, and continuously-calculated blood glucose estimates derived from a nonlinear state-space model of glucose and insulin reactions within a human body. The state-space model has user-entered values corresponding to their insulin and meal intake. The user's blood glucose is estimated from a combination of the discrete invasive blood glucose estimates, the discrete noninvasive blood glucose estimates and the continuously-calculated blood glucose estimate.
Resumen de: EP4541265A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; and a storage unit that stores the blood glucose measurement data, wherein the control unit stores the preset first verification data in the storage unit, and stores the blood glucose measurement data in the storage unit continuously to the first verification data.
Resumen de: EP4541276A1
The invention provides a non-invasive blood glucose monitoring device with a wearing fit detection function, comprising a substrate, a blood glucose monitoring module, an optical feedback sensing module and at least one light-blocking wall. The substrate defines a first setting area for disposing the blood glucose monitoring module and a second setting area for disposing the optical feedback sensing module. The second setting area is between an edge of the substrate and the first setting area. The optical feedback sensing module includes at least one light-emitting element and at least one light-receiving element. Each light-emitting element emits a light signal corresponding to at least one specific wavelength, and each light-receiving element receives the light signal corresponding to the at least one specific wavelength, after being reflected, as a basis for determining the wearing fit. The at least one light-blocking wall is located between the first setting area and the second setting area.
Resumen de: EP4541266A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; a storage unit that includes a plurality of storage areas and stores the blood glucose measurement data in the plurality of storage areas; and a communication unit that transmits the blood glucose measurement data stored in at least one of the plurality of storage areas to an external device, wherein the control unit determines the validity of the blood glucose measurement data stored in the plurality of storage areas, and controls the communication unit to transmit the blood glucose measurement data stored in at least one of the plurality of storage areas to the external device, based on a result of the determination.
Resumen de: EP4542560A1
Disclosed are methods, techniques, systems, and devices that are operable to compensate for the effects of pharmaceuticals on a user's analyte measurement values, such as glucose levels and/or ketone levels. The disclosed system is configured to enable medicament delivery application to enter a pharmaceutical mode. While in pharmaceutical mode, the medicament delivery application is operable to adjust medicament delivery constraints and other settings used by the medicament delivery application to respond to the effects of the pharmaceutical on the user's analyte measurement values.
Resumen de: EP4542574A2
Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are disclosed. In an embodiment, a method for transmitting data between a first communication device associated with an analyte sensor and a second communication device configured to provide user access to sensor-related information comprises: activating a transceiver of a first communication device associated with an analyte sensor at a first time; and establishing a two-way communication channel with the second communication device; wherein the activating comprises waking the transceiver from a low power sleep mode using a forced wakeup from the second communication device.
Resumen de: EP4541390A2
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal dosing of GLP-1 or co-formulation of GLP-1 and insulin. The size and frequency of the basal doses may be controlled by a medication delivery algorithm resident on the wearable drug delivery device based on a basal dosing history and readings from a continuous glucose monitor monitoring the glucose levels of the wearer of the device.
Resumen de: US2025125031A1
A device may receive, from a plurality of sensors, sensor data relating to a user. The device may include a plurality of types of sensors including a spectrometer and one or more of an accelerometer, a heart rate sensor, a blood pressure sensor, a blood sugar sensor, a perspiration sensor, a skin conductivity sensor, or an imaging sensor. The device may process the sensor data, from the plurality of types of sensors, relating to the user to determine a health condition of the user. The device may provide, via a user interface, information identifying the health condition of the user based on processing the sensor data, from the plurality of types of sensors, relating to the user.
Resumen de: US2025121133A1
Embodiments of devices and methods to maintain preservative concentration in a medication delivered using a medical device are provided. A barrier layer can be used to prevent migration of preservatives. A vent can be used to allow release of preservatives prior to delivery to the patient. An absorbent element can be used to maintain preservative concentration at a desired level. A filter can be used to capture particulates from the medication prior to delivery to a patient.
Resumen de: US2025120617A1
The invention provides a manufacturing method for a non-invasive blood glucose monitoring device, which comprises the following steps: providing a substrate; performing an injection molding process or an electroplating process, to form at least one light-blocking wall on the substrate, wherein each light-blocking wall includes a lower wall-structure and an upper wall-structure, and the lower wall-structure connects the substrate and the upper wall-structure connects the lower wall-structure; arranging a light-emitting element and a light-receiving element on the substrate and separating the light-emitting element and the light-receiving element by the at least one light-blocking wall; forming a packaging structure on the substrate in which the light-emitting element and the light-receiving element are packaged; and disposing a transparent cover on the packaging structure and the at least one light-blocking wall and limiting the transparent cover to a configuration height by the at least one light-blocking wall.
Nº publicación: US2025120619A1 17/04/2025
Solicitante:
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc
Resumen de: US2025120619A1
Disclosed herein are system, method, and computer program product embodiments for interconnecting a prediction visualization with user medical data for analyzing the impact of personal choices on future glucose levels. The prediction visualization is configured to generate predictions of glycemic impact based one or more inputs including choices involving diet and exercise and user medical data, such as the user's historical and current glucose levels. The prediction visualization is configured to be adjustable based on user input and the visualization is configured to dynamically update based on user input. The disclosed interface allows the user to adjust the sequencing of these decisions and portion sizes of meal choices and immediately generate new visualizations representing the impact on predicted future glucose levels.
BOPI
Sede Electrónica
